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Long-Term Dual Anti-Platelet Therapy in Patients Treated with Bare Metal
Stent Implantation: Results From the NHLBI Dynamic Registry
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Catalin Toma1, Joon S Lee1, David O Williams2, Kevin E Kip3, Suresh Mulukutla1
1University of Pittsburgh Medical Center, Pittsburgh, PA; 2Brigham and Women’s
Hospital, Boston, MA; 3University of South Florida, Tampa, FL
Background: In current practice, the duration of DAPT after BMS implantation
remains variable, and the utility of long term DAPT in patients who receive bare mental
stents remains unknown. Therefore, we sought to investigate the effect of extended
DAPT in BMS-treated patients and its effect on long term outcomes.
Methods: We analyzed data from consecutive patients who received bare metal stents
enrolled in Waves 4(2004) and 5(2006) of the NHLBI Dynamic Registry. Those
patients who remained event free during the first year of follow up were stratified
according to whether they were on DAPT at one year after stent implantation or not,
and a landmark analysis was performed. Patients were followed for up to four years
for the occurrence of cardiovascular events and death.
Results: A total of 526 patients with a mean age of 64 years were evaluated for the
12-month landmark, with 310 (59%) on DAPT at one year. There were no significant
differences in baseline characteristics between the two groups. In the landmark
analysis, there was a significantly lower 4-year rate of death in the group that continued
DAPT compared to the group that did not (Figure 1: 8.5% vs. 14.3%, p = 0.03).
Beneficial differences were preserved after multivariate and propensity adjustment.
Death Rates for BMS patients Event Free at One Year by Dual Anti-Platelet Therapy
Use
Conclusion: Following BMS implantation, those who remain on DAPT for at least
one year appear to have improved survival compared those who do not. These findings
suggest that extended use of Clopidogrel up to one year might be considered in those
who receive BMS, and do not otherwise have contraindications to longer term DAPT.
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The Association Between Duration of Clopidogrel Therapy After Saphenous
Vein Graft Intervention And Long-Term Death And Myocardial Infarction
Amit Sachdeva1, Sumati Bavisetty1, Gerald Beckham1, Vicken Aharonian1, Prakash
Mansukhani1, Gregg W Stone2, Naing Moore1, Ric Hyett1, Richard Contreras1,
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Background: In certain high-risk groups, such as patients undergoing saphenous vein
graft PCI, the association between clopidogrel duration and adverse cardiovascular
events has not been reported.
Methods: We identified consecutive patients undergoing saphenous vein graft PCI
between 2000-2009 in an integrated prepaid health care system. Clopidogrel utilization
was ascertained from pharmacy records. The date of the prescription and quantity of
tablets dispensed were recorded for every clopidogrel prescription filled by the patient
post-PCI. A multivariable logistic regression model was used to generate predicted
probabilities for all-cause mortality and myocardial infarction (MI) post-PCI. The
model was adjusted for age, gender, diabetes, hypertension, other comorbidities, stent
type, clopidogrel noncompliance, and use of cardioprotective medications.
Results: There were 576 patients who underwent saphenous vein graft PCI during the
study period. The mean age was 68 ± 10 years and 18% were female. The median
follow-up was 3-years. Longer duration of clopidogrel therapy was associated with a
lower predicted probability of death or MI post-PCI (see figure). There does not appear
to be a threshold effect after which continued clopidogrel therapy is no longer effective.
Conclusion: This is the first report, to our knowledge, to characterize the relationship
between duration of clopidogrel therapy and long-term adverse cardiovascular
outcomes after saphenous vein graft PCI. These data suggest that longer duration of
dual antiplatelet therapy with clopidogrel is associated with a significant reduction in
death and MI in this high-risk group.
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Background: The aim of the current study was to perform two separate meta-analyses
of available studies comparing low-molecular-weight heparins (LMWHs) versus
unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients
treated 1) with primary percutaneous coronary intervention (pPCI) or 2) with PCI after
thrombolysis.
Methods: All-cause mortality was the prespecified primary endpoint and major
bleeding complications were recorded as secondary endpoint. Relative risk (RR) with
95 % confidence interval (CI) and absolute risk reduction (ARR) were chosen as the
effect measure.
Results: Ten studies comprising 16286 patients were included. The median follow-up
was two months for the primary endpoint. Among LMWHs, enoxaparin was the
compound most frequently used. In the pPCI group LMWHs were associated with a
reduction in mortality (RR [95% CI] = 0.51 [0.41 - 0.64], p < 0.001, ARR = 3%) and
major bleeding (RR [95% CI] = 0.68 [0.49 - 0.94], p = 0.02, ARR = 2.0 %) as compared
to UFH. Conversely, no clear evidence of benefits with LWMHs was observed in the
PCI group after thrombolysis. Meta-regression showed that patients with higher
baseline risk had larger benefits from LMWHs (r = 0.72, p = 0.02).
Conclusion: LMWHs were associated with greater efficacy and safety than UFH in
STEMI patients treated with pPCI, with a significant relationship between risk profile
and clinical benefits. Based on this meta-analysis, LMWHs may be considered as a
preferred anticoagulant among STEMI patients undergoing pPCI.
TCT-175
Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in
Patients with Renal Insufficiency and Suspected Heparin-Induced
Thrombocytopenia
James W Wisler1, Jeffrey B Washam2, Richard C Becker1, 3
1Duke University Medical Center, Durham, NC; 2Duke Heart Center, Durham, NC;
3Duke Clinical Research Institute, Durham, NC
Background: Bivalirudin is indicated for patients with suspected heparin-induced
thrombocytopenia (HIT) and anticipated percutaneous coronary intervention. There
are limited data on dose selection among patients with renal insufficiency, particularly
when clinical conditions dictate a prolonged infusion (>24h).
Methods: The study cohort comprised 73 patients with renal dysfunction who received
bivalirudin for suspected HIT with or without acute coronary syndrome. We reviewed
individual pharmacy and medical records for laboratory and bivalirudin dosing
information, medical co-morbidities, and adverse clinical outcomes during
administration.
Results: Average duration of treatment was 10.2 ± 11.6 days. When estimated
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glomerular filtration rate (eGFR) (mL/min) was calculated by Cockcroft-Gault (CG),
the mean bivalirudin dose achieving a therapeutic aPTT (50-80 seconds) was 0.07 ±
0.04, 0.15 ± 0.08, and 0.16 ± 0.07 for patients with an eGFR between 15-30, 31-60,
and >60, respectively (P=NS for 31-60 vs. >60; P<0.001 for 15-30 vs. 31-60). When
eGFR (mL/min/1.73 m2) was calculated by the Modification of Diet in Renal Disease
(MDRD) formula, the mean dose acheiving a therapeutic aPTT was 0.07 ± 0.04, 0.12
± 0.07, and 0.20 ± 0.07 for patients with eGFR between 15-30, 31-60, >60, respectively
(P<0.001 for 31-60 vs. >60 and 15-30 vs. 31-60; figure). No differences in adverse
clinical outcomes were observed.
Conclusion: Patients with suspected HIT receiving prolonged bivalirudin in the setting
of renal dysfunction can be treated safely and effectively following dose adjustments
in those with MDRD-determined moderate and severe renal impairment.
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Background: Bleeding complicating acute coronary syndrome (ACS) invasive care
is associated with increased ischemic events and mortality. Current anticoagulants are
limited by unpredictable pharmacodynamics and lack of specific reversibility. We
evaluated the effects of the REG1 System, an RNA aptamer, direct factor IXa inhibitor,
pegnivacogin, and its active control agent, animaversen, on access and non-access site
bleeding.
Methods: RADAR was a phase 2 trial evaluating the safety and efficacy of
anticoagulation with REG1 in non-ST-elevation ACS and planned early catheterization
via femoral access. A total of 640 patients were randomized 2:1:1:2:2 to pegnivacogin
with 25%, 50%, 75%, or 100% reversal with anivamersen with sheath removal at 10
minutes, or to heparin with sheath removal per standard care. Access and non-access
site bleeding at 30 days was assessed (ACUITY scale).
Results: Overall bleeding rates were similar across groups, with a trend toward less
major bleeding with more complete pegnivacogin reversal. Bleeding severity and
locations are shown (Table). The 25% reversal arm was terminated early due to excess
bleeding. One patient in the heparin arm had an intracranial bleed. Most bleeding
occurred ≤48 hours of randomization (81.1% with REG1 vs. 80% with heparin).
Conclusion: In non-ST ACS patients undergoing early invasive management, major
bleeding occurs in 10% of cases and is most often related to the vascular access site.
The REG1 System, with ≥ 50% reversal and early sheath removal resulted in similar
rates and severity of bleeding compared with heparin and standard sheath removal.
TCT-177
In hospital and 30 day outcomes in all-comer percutaneous coronary
intervention with bivalirudin: Initial report of the prospective EUROVISION
Registry. Hamon M, Nienaber C, Galli S, Huber K, Gulba D, Hill J, Lafont A,
Cequier A, Bernstein D, Deliargyris E
Martial Hamon
CHU Caen, Caen, France
Background: The EUROVISION Registry was designed to capture patterns of use
and short term outcomes associated with the use of bivalirudin (BIV) during PCI
procedures in Europe.
Methods: A total of 2018 consecutive BIV-treated patients (75% male, mean age 65.5
years) were included from 58 sites in 5 countries (Germany, Italy, France, Austria,
United Kingdom). In-hospital and 30-day outcomes were collected and included:
Death, MI, stroke, revascularization, major and minor bleeding, stent thrombosis and
thrombocytopenia.
Results: Indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina
(16%) and stable angina (26%) with a median procedural duration of 28 minutes.
Overall, P2Y12 inhibitor preloading occurred in 95% of patients (91% clopidogrel
{65% with 600 mg and 33% with 300mg}, 9% prasugrel), 45% of patients received
other antithrombin therapy prior to PCI and were then switched to BIV, while
procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Activated clotting time
was checked in only 2.8% suggesting operator familiarity with BIV predictable mode
of action and treatment effect. Among STEMI patients, 62% received a post-procedural
BIV infusion for a median duration of 122 minutes. Safety measures included major
bleeding (1.6%), stroke (5/2018, 0.2%), thrombocytopenia (0/2018), and stent
thrombosis (6/2018, 0.3%). Overall mortality was 1.0%, myocardiaI infarction rate
was 1.1% and urgent revascularization was 0.8%.
Conclusion: Adaptation of BIV as the foundation for all-comer PCI (including high
percentage of STEMI and NSTEMI patients) is associated with excellent ischemic
protection and unsurpassed safety. The rates observed in EUROVISION compare
favorably to other large existing registry datasets.
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Use of the REG1 Anticoagulation System During PCI May Improve Bleeding
and Ischemic Complications Compared with Heparin: A PCI Substudy from
the Phase 2B RADAR Trial
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Background: REG1 consists of pegnivacogin, an RNA aptamer factor IX inhibitor,
and its active controlling agent, anivamersen. RADAR assessed the safety and efficacy
of REG1 in patients with acute coronary syndromes (ACS) undergoing catheterization
via femoral access. REG1’s safety and efficacy in patients undergoing PCI has not
been described.
Methods: Patients were randomized in a 2:1:1:2:2 fashion to REG1 with 25%, 50%,
75% or 100% reversal, or heparin. The primary safety and efficacy endpoints were a
composite of major and minor ACUITY bleeding and the composite of death,
myocardial infarction, urgent target vessel revascularization (TVR), or recurrent
ischemia through 30 days.
B47JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Adjunct Pharmacology
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
